logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Agenus Good News: Balstilimab Monotherapy Data Published in Gynecologic Oncology

Agenus Good News for Balstilimab Monotherapy Agenus ( AGEN ) announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer-reviewed journal  Gynecologic Oncology . From the...

Read More

August 27, 2021

0

Cassava Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Study in Alzheimer's Patients

Cassava Sciences Released a Statement  Cassava Sciences, Inc. ( SAV A ) - a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients...

Read More

August 27, 2021

0

Can-Fite Biopharma Has Encouraging News but Will It Enthuse Investors?

Can-Fite Biopharma Good News We learned, from Petach Tikva, Israel, that Can-Fite Biopharma ( CANF ) - a biotechnology company advancing its pipeline of small molecule drugs that address inflammatory, cancer and liver diseases, announced its completion of enrollment of...

Read More

September 2, 2021

0

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Johnson & Johnson's Janssen Pharmaceutical AKEEGA Johnson & Johnson ( JNJ )  owned Janssen Pharmaceutical announced that the U.S. FDA has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with...

Read More

August 15, 2023

0

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics CEO Letter to Shareholders Cognition Therapeutics ( CGTX ) today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024....

Read More

January 4, 2024

0

Can Excision BioTherapeutics Inc Cure HIV?!

Excision BioTherapeutics, Inc. IND Application for EBT-101 for HIV Accepted by the US FDA Excision BioTherapeutics, Inc. , which focuses on developing CRISPR-based therapies intended to cure viral infectious diseases, announced that the U.S. FDA has accepted the firm’s Investigational...

Read More

September 24, 2021

0

Sanofi to Acquire Inhibrx, Inc.

Sanofi to Acquire Inhibrx Inc Paris, January 23, 2024, Sanofi ( SNY ) and Inhibrx, Inc. ( INBX ) entered into a definitive agreement under which Sanofi agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx...

Read More

January 23, 2024

0

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference Indeed, today, Akero Therapeutics ( AKRO ) presented virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T. A live webcast...

Read More

October 24, 2023

0

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the Muscle Mass of Adults Pursuing Weight Loss by Various Means

Abbott Laboratories New PROTALITY™ for Maintaining Muscle Mass During Weight Loss Abbott Laboratories ( ABT ) announced the launch of its new PROTALITY™ brand. The high-protein nutrition shake is the first product to support the adults interested in pursuing weight loss...

Read More

February 1, 2024

0

Don't Miss the Enanta Pharmaceuticals Virtual Conference on October 19th - October 21st

Don't Miss Enanta Pharmaceuticals Virtual Conference Enanta Pharmaceuticals ( ENTA ) - a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data for EDP-235 - its lead oral...

Read More

October 11, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 108
  • 109
  • 110
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy